Arctic Vision, a China-based biotech company, announced on Monday that it has enrolled the first patient in a phase III clinical study assessing ARVN003, a proprietary pilocarpine formulation using its micro dosing platform Optejet, as a treatment to temporarily improve vision in adults with presbyopia in China.
The Phase III study, a double-masked, placebo-controlled, randomised, and multicentre trial, is to assess the efficacy and safety of the product in achieving temporary improvement of vision in adults with presbyopia. It is the first clinical trial approved in China for presbyopia drugs and the company's study represents the first patient enrolment in a Phase III clinical trial for presbyopia drugs in China. Presbyopia is a physiological condition that makes it difficult to read and work in near distance.
The company received an exclusive license in August 2020 for the development and commercialisation of ARVN003 (MicroLine) in Greater China and South Korea from United States-based Eyenovia.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval